Creates the Global Leader in the International Medical Cannabis Market: Aphria will leverage Nuuvera’s numerous relationships in Germany, Italy, Spain, the United Kingdom, Malta, Israel, Lesotho and Uruguay. Combined with Aphria’s existing agreements in Australia, the combined company establishes a leading international footprint among Canadian licensed producers, and expands Aphria’s processing and manufacturing capabilities globally........Read More
Over 100 interested undertakings answered BfArM's initial call for competition. Nuuvera is one of 10 remaining bidders asked to submit an offer in the public procurement procedure.
Lorne Abony, CEO of Nuuvera Inc. stated, "We are tremendously excited about BfArM's decision, and for the headway Nuuvera has made in Germany, which is one of the largest markets in the world to legalize cannabis for medical usage.".......Read More
Nuuvera recently purchased a 11,300 square-foot property in Bad Bramstedt, in northern Germany, to build a premium vault storage system equipped with state-of-the-art security and related technology. The facility is expected to meet the most stringent requirements for the storage of controlled substances in Germany and the EU.
Lorne Abony, the CEO of Nuuvera, said that the new facility will ensure the company can continue to develop into a major supplier of medical cannabis products to German consumers........Read More
Under the terms of the LOI, CC Pharma, a leading distributor of pharmaceutical products to over 13,000 pharmacies in Germany, has agreed to import approximately 1,200 kilograms of medical cannabis from Nuuvera in 2018. The completion of the transaction is subject to and conditional upon the execution of the definitive agreement, the approval from the TSX Venture Exchange, and the approval of the relevant Canadian and German governmental authorities.
Lorne Abony, the CEO of Nuuvera, said the agreement will bring together two companies with a strong commitment to high standards of quality and consistency........Read More
In connection with the trading delay, Ungad Chadda, President, Capital Formation, Toronto Stock Exchange, TSX Venture Exchange, provided the following statement to Nuuvera and its shareholders:
"We are honoured to have Nuuvera join the TSX Venture Exchange and want to assure the public that Nuuvera has been formally approved as a listed company on the TSX Venture Exchange. We also take this opportunity to apologize to Nuuvera and its stakeholders on the delayed first day of trading which was caused by a clerical error. Nuuvera will be available for trading at the open on Tuesday, January 9, 2018, and we look forward to hosting the Nuuvera team to open the market this Wednesday, January 10, 2018 to celebrate their listing.".......Read More
Malta’s law regulating medical marijuana is about to become less restricted, Prime Minister Joseph Muscat has announced.
“Cabinet will start discussing changes to the law regulating medical marijuana in November,” Muscat told a media briefing yesterday. “It is only when we update the law on medical marijuana that we’ll start discussing possible legalisation for personal use.”........Read More
Nuuvera is engaged in the testing, formulation, production, extraction and sale of medicinal cannabis products in Canada and other legal International jurisdictions (excluding the United States, where no Nuuvera business is conducted). Nuuvera carries on its business through its subsidiaries, ARA-Avanti Rx Analytics Inc. (“Avanti”), of which Nuuvera indirectly holds 51%, and Avalon Pharmaceuticals Inc. (“Avalon”), an indirect, wholly-owned subsidiary of Nuuvera.
Avanti is a “Licensed Dealer” as defined pursuant to the Narcotic Control Regulations and holds an establishment license evidencing its facility’s compliance with Health Canada’s Good Manufacturing Practices requirements. The business of Avanti is the extraction, testing and analysis of cannabis and cannabis derivative products on behalf of “Licensed Producers” and other authorized individuals under the Narcotic Control Regulations and the Access to Cannabis for Medical Purposes Regulations. Avanti does not grow, distribute, nor sell/commercialize cannabis. In addition, Avanti offers a comprehensive menu of services in respect of controlled substances beyond cannabis including analytical research and development and quality control, as well as quality assurance and regulatory consulting........Read More
The hemp plant has been hugely overlooked as a great alternative for pain management and other medical conditions. The partnership between the two companies addresses many of the concerns of the unsettling psychotropic effects of THC found in cannabis, especially in the elderly and high anxiety patient population. In comparison, hemp contains low THC cannabis content and many beneficial cannabinoids, including cannabidiol (CBD). Hemp is also known for its diverse and robust anti-inflammatory flavonoids content, along with its high nutritional value because of its high essential polyunsaturated fatty acids (omega 3's), which matches that of the human body. Properly administered, medical non-psychotropic cannabis provides real alternatives to more addictive type drugs, including opioids........Read More
Canadian medical marijuana patients could soon find themselves ditching the pipe, bong or vaporizer for a topical cream or an oral spray that contains the active ingredients of cannabis, according to the CEO of biotechnology company Delivra Corp. .......Read More
It is the intention of the joint venture for BIO to be the preferred purchaser from ARA of all BIO’s and ADC’s products containing algae, hemp oil, and cannabis extracted oils, and/or their compounds. ADC will be responsible for the provision of raw materials, or if required by law, will arrange for the provision of raw materials to ARA for processing. ARA will be responsible for processing the raw materials into finished bulk goods and/or packaged products, and shipping same to BIO’s licensed clients/sellers and research organizations. ARA will process materials according to agreed prices and specifications, which may be modified from time to time. The initial term of the joint venture is for three (3) years, effective April 10, 2017, renewing automatically unless notice is given from one party to the other to terminate. In addition, the joint venture may be terminated upon the occurrence of a material breach that remains uncured for 60 days.” .......Read More
“We are pleased to enter into the Importation Agreement with Avanti with a view to working together to provide Canadians with a broader supply of cannabidiol (“CBD”) oil and cannabis extract oils, and other related products from our Uruguayan operations at competitive price points,” commented Guillermo Delmonte, Chief Executive Officer of ICC. “In addition, Avanti brings to the table extensive knowledge and expertise in the field of quality control, cannabis extraction, and CBD purification. The business relationship with Avanti is expected to allow ICC to leverage Avanti’s dealer license and laboratory facilities in order to facilitate sales in Canada, and represents a positive next step in ICC’s strategy to export to global markets where lawful.” .......Read More
Avanti is a leading Health Canada approved contract organization specializing in the field of controlled drugs and substances particularly in the area of medicinal marihuana, hemp, cannabinoids, and marihuana based concentrated products. Avanti offers a comprehensive menu of services ranging from analytical research and development, and quality control testing, marihuana extraction, cannabinoid purification, cannabis infused-product formulation, and cannabis waste management, as well as quality assessment and regulatory consulting. .......Read More
“The Federal Government of Canada has numerous concerns, and barriers to overcome, before legalizing cannabis, including stricter regulatory controls. The partnership between the three companies addresses many of these concerns, providing greater safety and efficacy of medical cannabis specific products for the patient, with products that provide consistent, accurate dosing, and that are manufactured under pharmaceutical GMP Standards,” said Dr. Joseph Gabriele, CEO of Delivra. “This collaboration between Delivra, Dosecann and Avanti addresses an exploding field of medicine by seeking to standardize, validate, package and distribute cannabis products in innovative mono-dose delivery platforms to licensed producers and other future legal distribution networks, ultimately meeting the needs of the patient.” .......Read More
Paul Ramsay, Chairman and President of the Company said, “This collaboration is a vital piece of our corporate development strategy. Our relationship with ARA will assist us immensely in the development of unique products both in the medical cannabis category, as well as in unique formulations utilizing cannabis and algae oils. It dove-tails beautifully with our recently announced research relationships with two universities, and we believe will help fast-track us to revenue.” .......Read More
According to a Government of Canada website, the following is a list of laboratories that have a current Dealers License under the Narcotic Control Regulations and who are licensed to conduct special activities with cannabis. .......Read More
Drug products and dietary supplements for the US market will soon have to comply with the new elemental impurities requirements and testing set forth by the USP General Chapters <232> Elemental Impurities—Limits, <233> Elemental Impurities—Procedures, and <2232> Elemental Contaminants in Dietary Supplements. The USP recognized that the current chapter <231> Heavy Metals was obsolete, and it will be eliminated completely on 1/1/2018, when also the new chapters will be officially implemented.
These new chapters include the use of modern procedures and analytical equipment, and establish the limits for acceptable levels of elemental impurities in drug products and dietary supplements. These changes will affect not just the drug manufacturers but also the raw materials supplier for active pharmaceutical ingredients (APIs) and/or excipients